Search results for "diabetic"

showing 10 items of 486 documents

Glucose regulation and grip strength in adults: Findings from the Helsinki Birth Cohort Study.

2021

Aim: this study aimed to assess the association between grip strength and glucose regulation in a cross-sectional setting.Methods: using data from the Helsinki Birth Cohort Study, 924 men and 953 women were studied at a mean age of 61.6 years. Grip strength was assessed in the dominant hand using a Newtest Grip Force dynamometer. A standard 2-h 75 g oral glucose tolerance test (OGTT) was used to define glucose regulation. The participants were classified into four groups: normoglycaemia, prediabetes (impaired fasting glucose or impaired glucose tolerance), newly diagnosed diabetes and previously known diabetes. The association between grip strength and glucose regulation was assessed using …

Blood GlucoseMaleAgingHealth (social science)EpidemiologyPhysical fitnesspuristusvoimaprediabetesImpaired glucose toleranceCohort StudiesMUSCLE STRENGTHGrip strengthDiabetes mellitus0302 clinical medicine030212 general & internal medicinePrediabetesepidemiologiakohorttitutkimusRISK2. Zero hungerdiabetesHand Strength3. Good healthfyysinen kuntodiabetes mellitusepidemiologyFemaleHEALTHmedicine.medical_specialtyPrediabetic State03 medical and health sciencesAGEDiabetes mellitusInternal medicinemedicineHumansOLDER-ADULTS030214 geriatricsbusiness.industryDIABETES-MELLITUSPhysical fitnessmedicine.diseaseImpaired fasting glucoseikääntyminenPHYSICAL-ACTIVITYCross-Sectional StudiesGlucoseDiabetes Mellitus Type 2Grip strengthMOBILITYgrip strength3121 General medicine internal medicine and other clinical medicinephysical fitnessBlood sugar regulationGeriatrics and GerontologybusinessPrediabetesGerontologyBody mass indexArchives of gerontology and geriatrics
researchProduct

Severe hypoglycemia is associated with antidiabetic oral treatment compared with insulin analogs in nursing home patients with type 2 diabetes and de…

2015

Abstract Objectives Severe hypoglycemia is associated with cognitive decline and dementia in older persons with type 2 diabetes. The role of antidiabetic treatments on severe hypoglycemia is unknown in dementia. The aims were to determine the prevalence of severe hypoglycemic events and investigate associations among severe hypoglycemic and specific antidiabetic treatments (classes of oral agents and types of insulin analogs) in a large sample of nursing home patients with diabetes according to dementia status. Design Cross-sectional observational study. Setting A total of 150 nursing homes across Italy. Participants A total of 2258 patients with type 2 diabetes (dementia = 1138, no dementi…

Blood GlucoseMaleAgingSevere hypoglycemia dementia insulin analogs antidiabetic oral agents agingmedicine.medical_treatmentInsulin analogAdministration OralType 2 diabetesSeverity of Illness IndexInsulin AntagonistsReference ValuesOdds RatioPrevalenceHomes for the AgedInsulinReference ValueCognitive declineNursing (all)2901 Nursing (miscellaneous)General NursingAged 80 and overInsulin AntagonistMedicine (all)Health PolicyAging; Antidiabetic oral agents; Dementia; Insulin analogs; Severe hypoglycemia; Administration Oral; Age Distribution; Aged; Aged 80 and over; Blood Glucose; Confidence Intervals; Cross-Sectional Studies; Dementia; Diabetes Mellitus Type 2; Female; Homes for the Aged; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Antagonists; Italy; Logistic Models; Male; Middle Aged; Nursing Homes; Odds Ratio; Prevalence; Prognosis; Reference Values; Risk Assessment; Severity of Illness Index; Sex Distribution; Sulfonylurea Compounds; Nursing (all)2901 Nursing (miscellaneous); Health PolicyGeneral MedicineMiddle AgedPrognosisSulfonylurea CompoundNursing HomeItalyFemaleHumanmedicine.medical_specialtyLogistic ModelPrognosiHypoglycemiaelderly patientsRisk AssessmentAge DistributionInternal medicineDiabetes mellitusmedicineConfidence IntervalsDementiaHumansHypoglycemic AgentsSex DistributionAgedAntidiabetic oral agentCross-Sectional StudieSevere hypoglycemiaHypoglycemic Agentbusiness.industryInsulinOdds ratiomedicine.diseaseHypoglycemiaNursing HomesEndocrinologyCross-Sectional StudiesLogistic ModelsSulfonylurea CompoundsDiabetes Mellitus Type 2DementiaGeriatrics and GerontologybusinessConfidence IntervalBody mass indexJournal of the American Medical Directors Association
researchProduct

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-…

2017

Background: \ud Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.\ud \ud Methods: \ud In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-…

Blood GlucoseMaleEXENATIDEType 2 diabetes030204 cardiovascular system & hematologyBody Mass Indexlaw.inventionPlacebosImpaired glucose toleranceMELLITUS3.0 MG0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawPREVENTION PROGRAM OUTCOMESPrediabetesPREVENTION PROGRAM OUTCOMES; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; CLINICAL-TRIAL; OBESE SUBJECTS; 3.0 MG; REGRESSION; EXENATIDE; MELLITUSSubcutaneousMedicine (all)General MedicineMiddle AgedAdult; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Obesity; Placebos; Prediabetic State; Risk Reduction Behavior; Treatment Outcome; Weight Loss3. Good healthTreatment OutcomeFemaleLIFE-STYLEType 2OBESE SUBJECTSmedicine.drugAdultmedicine.medical_specialtyInjections Subcutaneous030209 endocrinology & metabolismPlaceboIncretinsGlucagon-Like Peptide-1 ReceptorInjectionsCLINICAL-TRIALPrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEDouble-Blind MethodDiabetes mellitusInternal medicineWeight LossREGRESSIONDiabetes MellitusmedicineHumansHypoglycemic AgentsObesityLiraglutidebusiness.industryBody WeightLiraglutidemedicine.diseaseClinical trialEndocrinologyDiabetes Mellitus Type 2Human medicinebusinessRisk Reduction Behavior[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe Lancet
researchProduct

Remodelling of biological parameters during human ageing: evidence for complex regulation in longevity and in type 2 diabetes.

2013

Factor structure analyses have revealed the presence of specific biological system markers in healthy humans and diseases. However, this type of approach in very old persons and in type 2 diabetes (T2DM) is lacking. A total sample of 2,137 Italians consisted of two groups: 1,604 healthy and 533 with T2DM. Age (years) was categorized as adults (≤65), old (66-85), oldest old (>85-98) and centenarians (≥99). Specific biomarkers of routine haematological and biochemical testing were tested across each age group. Exploratory factorial analysis (EFA) by principal component method with Varimax rotation was used to identify factors including related variables. Structural equation modelling (SEM) wa…

Blood GlucoseMaleGerontologyAgingAgeing Diabetes longevityPhysiologyType 2 diabetescentenarianHemoglobinsLeukocyte CountAged 80 and overPrincipal Component AnalysisHematologic TestsbiologyGeneral MedicineMiddle AgedExplained variationExploratory factor analysisexploratory factor analysiC-Reactive ProteinCholesteroldiabetic patientsItalyFemaleAnalysis of varianceAdultSTRUCTURAL EQUATION MODELINGAdolescentVarimax rotationLongevityAGEINGArticlemedicineHumansTriglyceridesAgedSettore MED/04 - Patologia GeneraleAnalysis of VarianceChi-Square DistributionC-reactive proteinFibrinogenmedicine.diseaseDiabetes Mellitus Type 2Ageingbiology.proteinGeriatrics and GerontologyFactor Analysis StatisticalChi-squared distributionBiomarkers
researchProduct

Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospe…

2019

Abstract Aims According to cardiovascular outcome trials, some sodium‐glucose contransporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are recommended for secondary cardiovascular prevention in type 2 diabetes (T2D). In this real‐world study, we compared the simultaneous reductions in HbA1c, body weight and systolic blood pressure after initiation of dapagliflozin or GLP‐1RA as second or a more advanced line of therapy. Materials and methods DARWIN‐T2D was a retrospective multi‐centre study conducted at diabetes specialist clinics in Italy that compared T2D patients who initiated dapagliflozin or GLP‐1RA (exenatide once weekly or liraglutide). Data were c…

Blood GlucoseMaleGlycated Hemoglobin AEndocrinology Diabetes and MetabolismBlood PressureType 2 diabetes030204 cardiovascular system & hematologySettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineEndocrinologyGlucosidesClinical endpointMedicineDapagliflozinGLP-1 analogueMiddle AgedTreatment Outcomeglycaemic controlantidiabetic drug; dapagliflozin; GLP-1 analogue; glycaemic control; observational studyCombinationOriginal ArticleDrug Therapy CombinationFemaleType 2medicine.drugAdultmedicine.medical_specialty030209 endocrinology & metabolismGlucagon-Like Peptide-1 Receptor03 medical and health sciencesDrug TherapyGLP-1 analogue; antidiabetic drug; dapagliflozin; glycaemic control; observational studyGLP‐1 analogueInternal medicineDiabetes mellitusInternal MedicineDiabetes MellitusHumansHypoglycemic AgentsBenzhydryl CompoundsAgedRetrospective StudiesGlycated Hemoglobinantidiabetic drugantidiabetic drug; dapagliflozin; GLP-1 analogue; glycaemic control; observational study; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus Type 2; Diabetic Angiopathies; Drug Therapy Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Retrospective Studies; Treatment Outcomebusiness.industryLiraglutideBody WeightRetrospective cohort studyOriginal ArticlesdapagliflozinLiraglutidemedicine.diseaseBlood pressureDiabetes Mellitus Type 2chemistryPropensity score matchingExenatideobservational studybusinessAntidiabetic drug dapagliflozin GLP-1 analogue glycaemic control observational studyDiabetic Angiopathies
researchProduct

Beneficial Effect of Docosahexanoic Acid and Lutein on Retinal Structural, Metabolic, and Functional Abnormalities in Diabetic Rats

2009

To assess the effect of docosahexanoic acid (DHA) and lutein (both compounds with anti-inflammatory and antioxidant properties) on experimental diabetic retinopathy.Male Wistar rats were studied: non-diabetic controls, untreated diabetic controls, and diabetic rats were treated with DHA and lutein or the combination of DHA + insulin and lutein + insulin for 12 weeks. Oxidative stress and inflammatory markers, apoptosis, and functional tests were studied to confirm biochemical and functional changes in the retina of diabetic rats. Malondialdehyde (MDA), glutathione concentrations (GSH), and glutathione peroxidase activity (GPx) were measured as oxidative stress markers. TUNEL assay and caspa…

Blood GlucoseMaleLuteingenetic structuresmedicine.medical_treatmentApoptosismedicine.disease_causeAntioxidantschemistry.chemical_compoundMalondialdehydeInsulinFluorescent Antibody Technique Indirectchemistry.chemical_classificationCaspase 3NitrotyrosineGlutathione peroxidaseAnti-Inflammatory Agents Non-Steroidalfood and beveragesMalondialdehydeGlutathioneSensory SystemsDrug Therapy Combinationmedicine.medical_specialtyDocosahexaenoic AcidsEnzyme-Linked Immunosorbent AssayBiologyRetinaDiabetes Mellitus ExperimentalCellular and Molecular NeuroscienceDiabetes mellitusInternal medicineElectroretinographyIn Situ Nick-End LabelingmedicineAnimalsRats WistarGlutathione PeroxidaseDiabetic RetinopathyInsulinLuteinGlutathionemedicine.diseaseeye diseasesRatsOxidative StressOphthalmologyEndocrinologychemistryTyrosinesense organsBiomarkersOxidative stressCurrent Eye Research
researchProduct

Glucose regulation and pain in older people-The Helsinki Birth Cohort Study

2021

Aims: To assess if individuals with diabetes or prediabetes report more pain or have increased use of pain medication compared to normoglycaemic individuals. Methods: Using cross-sectional data, we studied 928 men and 1075 women from the Helsinki Birth Cohort Study in 2001-2004 at a mean age of 61.5 years. Glucose regulation was assessed with a 2-h 75 g oral glucose tolerance test, and applying World Health Organization criteria, participants were defined as having normoglycaemia, prediabetes (impaired fasting glucose or impaired glucose tolerance), newly diagnosed diabetes or previously diagnosed diabetes. Self-reported pain intensity and interference during the previous 4 weeks was estima…

Blood GlucoseMalePREDICTOREpidemiologyIMPACTEndocrinology Diabetes and MetabolismglukoosiaineenvaihduntaprediabetesDISEASECohort StudiesImpaired glucose tolerance0302 clinical medicinepain030212 general & internal medicinePrediabetesepidemiologiaPOPULATION2. Zero hungereducation.field_of_studyNutrition and DieteticsdiabetesDiabetesMiddle Aged3. Good healthPREVALENCEFemaleepidemiologyFamily Practiceikääntyneetmedicine.medical_specialtyPopulationPain030209 endocrinology & metabolismPrediabetic State03 medical and health sciencesInternal medicineDiabetes mellitusGlucose IntoleranceInternal MedicinemedicineHumansTOLERANCEeducationAgedbusiness.industryBeck Depression Inventorykipumedicine.diseaseImpaired fasting glucoseLIFEHIGH-RISKCross-Sectional StudiesGlucose3121 General medicine internal medicine and other clinical medicinekrooninen kipuBlood sugar regulationbusinessBody mass indexPrediabetesPERIPHERAL NEUROPATHY
researchProduct

The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with …

2012

Aims The objective was to assess the consistency of effect of switching to ezetimibe/simvastatin 10/20 mg versus doubling the baseline statin dose (to simvastatin 40 mg or atorvastatin 20 mg) or switching to rosuvastatin 10 mg across subgroups of subjects with (n = 617) and without (n = 191) metabolic syndrome (MetS). Methods This was a post hoc analysis of a randomized, double-blind, 6-week study of adults 18–79 years with cardiovascular disease and diabetes mellitus with low-density lipoprotein cholesterol (LDL-C) ≥70 and ≤160 mg/dl. The percent change in LDL-C and other lipids was estimated within each subgroup separately. Safety and tolerability were assessed. Results In subjects with M…

Blood GlucoseMaleSimvastatinEndocrinology Diabetes and MetabolismAtorvastatinEzetimibe Simvastatin Drug CombinationPharmacologyEndocrinologyAtorvastatinMedicineRosuvastatin CalciumMetabolic SyndromeSulfonamidesAnticholesteremic AgentsFastingMiddle AgedDrug CombinationsTreatment OutcomeTolerabilityCardiovascular Diseaseslipids (amino acids peptides and proteins)Drug Therapy CombinationFemalemedicine.drugAdultmedicine.medical_specialtyStatinAdolescentmedicine.drug_classUrologyDrug Administration ScheduleEzetimibeDouble-Blind MethodDiabetes mellitusInternal MedicineHumansRosuvastatinPyrrolescardiovascular diseasesAgedApolipoproteins Bbusiness.industrynutritional and metabolic diseasesCholesterol LDLmedicine.diseaseFluorobenzenesDiabetes Mellitus Type 1PyrimidinesDiabetes Mellitus Type 2SimvastatinHeptanoic AcidsAzetidinesMetabolic syndromebusinessDiabetic AngiopathiesDiabetes, obesitymetabolism
researchProduct

Evidence for a dysfunction and disease-promoting role of the circadian clock in the diabetic retina.

2021

Diabetic retinopathy is a major complication of chronic hyperglycemia and a leading cause of blindness in developed countries. In the present study the interaction between diabetes and retinal clocks was investigated in mice. It was seen that in the db/db mouse - a widely used animal model of diabetic retinopathy - clock function and circadian regulation of gene expression was disturbed in the retina. Remarkably, elimination of clock function by Bmal1-deficiency mitigates the progression of pathophysiology of the diabetic retina. Thus high-fat diet was seen to induce histopathology and molecular markers associated with diabetic retinopathy in wild type but not in Bmal1-deficient mice. The d…

Blood GlucoseMalemedicine.medical_specialtyCircadian clockCLOCK ProteinsDiseaseChronobiology DisordersPathogenesisCellular and Molecular Neurosciencechemistry.chemical_compoundMiceDiabetes mellitusInternal medicineCircadian ClocksRNA Ribosomal 18SMedicineAnimalsRNA MessengerRetinaDiabetic Retinopathybusiness.industryGlyceraldehyde-3-Phosphate DehydrogenasesRetinalDiabetic retinopathymedicine.diseaseSensory SystemsPathophysiologyCircadian RhythmMice Inbred C57BLOphthalmologyDisease Models Animalmedicine.anatomical_structureEndocrinologychemistryMicroscopy FluorescenceFemalebusinessExperimental eye research
researchProduct

Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery di…

2006

Aims: Although diabetes is known to be a major contributor to cardiovascular diseases, as well as an independent predictor for adverse outcomes in patients with coronary artery disease (CAD), information on the prognosis of patients with CAD and newly diagnosed diabetes or impaired glucose regulation (IGR) is scarce. The objective of this study was to explore 1-year outcome in relation to different glucometabolic states of patients participating in the Euro Heart Survey on diabetes and the heart. Methods and results: In 4676 out of 4961 patients, information on the relation between 1-year outcome and glucometabolic state, which was based on oral glucose tolerance test (OGTT) or fasting gluc…

Blood GlucoseMalemedicine.medical_specialtyDiabetic AngiopathiePrognosiImpaired glucose regulationEuro Heart SurveyMyocardial InfarctionCoronary Artery DiseaseDiabeteFollow-Up StudieCoronary artery diseaseImpaired glucose toleranceSDG 3 - Good Health and Well-beingInternal medicineDiabetes mellitusmedicineHumansSurvival analysisAgedbusiness.industryHazard ratioMiddle Agedmedicine.diseaseImpaired fasting glucosePrognosisSurvival AnalysisStrokeEndocrinologyBlood sugar regulationFemaleCardiology and Cardiovascular MedicinebusinessComplicationDiabetic AngiopathiesHumanFollow-Up StudiesEuropean heart journal
researchProduct